A citation-based method for searching scientific literature

Surender Kumar, Pradeep G Talwalkar, Sambit Das, Soumik Goswami. Indian J Endocrinol Metab 2019
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100

Understanding EMPA-REG OUTCOME.
Marcel H A Muskiet, Daniël H van Raalte, Erik J M van Bommel, Mark M Smits, Lennart Tonneijck. Lancet Diabetes Endocrinol 2015
48
100

Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America.
Shannon M Dunlay, Michael M Givertz, David Aguilar, Larry A Allen, Michael Chan, Akshay S Desai, Anita Deswal, Victoria Vaughan Dickson, Mikhail N Kosiborod, Carolyn L Lekavich,[...]. J Card Fail 2019
17
100

Metabolism of the failing heart and the impact of SGLT2 inhibitors.
Alvaro Garcia-Ropero, Carlos G Santos-Gallego, M Urooj Zafar, Juan J Badimon. Expert Opin Drug Metab Toxicol 2019
23
100

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Michael R MacDonald, Mark C Petrie, Fumi Varyani, Jan Ostergren, Eric L Michelson, James B Young, Scott D Solomon, Christopher B Granger, Karl Swedberg, Salim Yusuf,[...]. Eur Heart J 2008
344
100

Heart failure: preventing disease and death worldwide.
Piotr Ponikowski, Stefan D Anker, Khalid F AlHabib, Martin R Cowie, Thomas L Force, Shengshou Hu, Tiny Jaarsma, Henry Krum, Vishal Rastogi, Luis E Rohde,[...]. ESC Heart Fail 2014
436
100

Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
Mattia Galli, Domenico D'Amario, Carmelo Sofia, Marcello Vaccarella, Filippo Crea, Nadia Aspromonte. Expert Opin Drug Metab Toxicol 2018
2
100

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Fumitaka Soga, Hidekazu Tanaka, Kazuhiro Tatsumi, Yasuhide Mochizuki, Hiroyuki Sano, Hiromi Toki, Kensuke Matsumoto, Junya Shite, Hideyuki Takaoka, Tomofumi Doi,[...]. Cardiovasc Diabetol 2018
72
100

Heart Failure in Type 2 Diabetes Mellitus.
Helena C Kenny, E Dale Abel. Circ Res 2019
119
100


High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes.
L J M Boonman-de Winter, F H Rutten, M J M Cramer, M J Landman, A H Liem, G E H M Rutten, A W Hoes. Diabetologia 2012
133
100

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
Silvio E Inzucchi, Mikhail Kosiborod, David Fitchett, Christoph Wanner, Uwe Hehnke, Stefan Kaspers, Jyothis T George, Bernard Zinman. Circulation 2018
58
100

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
215
100

Diabetic cardiomyopathy.
Matthew Meng Yang Lee, John J V McMurray, Ana Lorenzo-Almorós, Søren Lund Kristensen, Naveed Sattar, Pardeep S Jhund, Mark C Petrie. Heart 2019
21
100


Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Remo H M Furtado, Marc P Bonaca, Itamar Raz, Thomas A Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
100
100

Effect of diabetes and hypertension on left ventricular diastolic function in a high-risk population without evidence of heart disease.
Cesare Russo, Zhezhen Jin, Shunichi Homma, Tatjana Rundek, Mitchell S V Elkind, Ralph L Sacco, Marco R Di Tullio. Eur J Heart Fail 2010
59
100

Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Barry H Greenberg, William T Abraham, Nancy M Albert, Karen Chiswell, Robert Clare, Wendy Gattis Stough, Mihai Gheorghiade, Christopher M O'Connor, Jie Lena Sun, Clyde W Yancy,[...]. Am Heart J 2007
102
100

New type of cardiomyopathy associated with diabetic glomerulosclerosis.
S Rubler, J Dlugash, Y Z Yuceoglu, T Kumral, A W Branwood, A Grishman. Am J Cardiol 1972
100

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.
Dean T Eurich, Sumit R Majumdar, Finlay A McAlister, Ross T Tsuyuki, Jeffrey A Johnson. Diabetes Care 2005
266
100

Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications.
Naresh Kumar, Ankit Garg, Deepak L Bhatt, Sandra Sabongui, Naveen Gupta, Sundeep Chaudhry, Ross Arena, Subodh Verma. Can J Physiol Pharmacol 2018
9
100

Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Carlos G Santos-Gallego, Alvaro Garcia-Ropero, Donna Mancini, Sean P Pinney, Johanna P Contreras, Icilma Fergus, Vivian Abascal, Pedro Moreno, Farah Atallah-Lajam, Ronald Tamler,[...]. Cardiovasc Drugs Ther 2019
32
100


Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.
Guanghong Jia, Michael A Hill, James R Sowers. Circ Res 2018
375
100


Insulin resistance and heart failure: molecular mechanisms.
Annayya R Aroor, Chirag H Mandavia, James R Sowers. Heart Fail Clin 2012
102
100

Role of diabetes in congestive heart failure: the Framingham study.
W B Kannel, M Hjortland, W P Castelli. Am J Cardiol 1974
100

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
John J V McMurray, David L DeMets, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna M Langkilde, Felipe A Martinez, Olof Bengtsson, Piotr Ponikowski, Marc S Sabatine,[...]. Eur J Heart Fail 2019
99
100

Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice.
Yusuke Kashiwagi, Tomohisa Nagoshi, Takuya Yoshino, Toshikazu D Tanaka, Keiichi Ito, Tohru Harada, Hiroyuki Takahashi, Masahiro Ikegami, Ryuko Anzawa, Michihiro Yoshimura. PLoS One 2015
63
100

The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.
Anne Pernille Ofstad, Dan Atar, Lars Gullestad, Gisle Langslet, Odd Erik Johansen. Heart Fail Rev 2018
22
100

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus.
Hector E Tamez, Alejandra L Tamez, Lucas A Garza, Mayra I Hernandez, Ana C Polanco. J Diabetes Metab Disord 2015
26
100

Empagliflozin directly improves diastolic function in human heart failure.
Steffen Pabel, Stefan Wagner, Hannah Bollenberg, Philipp Bengel, Árpád Kovács, Christian Schach, Petros Tirilomis, Julian Mustroph, André Renner, Jan Gummert,[...]. Eur J Heart Fail 2018
70
100

Updating experimental models of diabetic cardiomyopathy.
J Fuentes-Antrás, B Picatoste, A Gómez-Hernández, J Egido, J Tuñón, Ó Lorenzo. J Diabetes Res 2015
49
100

Epidemiology of diabetes.
Nita Gandhi Forouhi, Nicholas J Wareham. Medicine (Abingdon) 2014
192
100


Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study.
Guifeng Xu, Buyun Liu, Yangbo Sun, Yang Du, Linda G Snetselaar, Frank B Hu, Wei Bao. BMJ 2018
127
100

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
100


The association between glucose abnormalities and heart failure in the population-based Reykjavik study.
Inga S Thrainsdottir, Thor Aspelund, Gudmundur Thorgeirsson, Vilmundur Gudnason, Thordur Hardarson, Klas Malmberg, Gunnar Sigurdsson, Lars Rydén. Diabetes Care 2005
173
100

Heart Failure in Patients with Diabetes Mellitus.
Giuseppe Mc Rosano, Cristiana Vitale, Petar Seferovic. Card Fail Rev 2017
50
100

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca,[...]. Endocr Pract 2019
158
100

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
100

Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population: Stratification by Diabetic Glycemic Control and Medication Intensification.
Claire A Lawson, Peter W Jones, Lucy Teece, Sandra B Dunbar, Petar M Seferovic, Kamlesh Khunti, Mamas Mamas, Umesh T Kadam. JACC Heart Fail 2018
22
100

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
100

Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry.
Marco Dauriz, Giovanni Targher, Cécile Laroche, Pier Luigi Temporelli, Roberto Ferrari, Stephan Anker, Andrew Coats, Gerasimos Filippatos, Maria Crespo-Leiro, Alexandre Mebazaa,[...]. Diabetes Care 2017
42
100

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
916
100

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
100


Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease.
Hassan Khan, Stefan D Anker, James L Januzzi, Darren K McGuire, Naveed Sattar, Hans Juergen Woerle, Javed Butler. J Card Fail 2019
9
100

Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.
Søren L Kristensen, David Preiss, Pardeep S Jhund, Iain Squire, José Silva Cardoso, Bela Merkely, Felipe Martinez, Randall C Starling, Akshay S Desai, Martin P Lefkowitz,[...]. Circ Heart Fail 2016
158
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.